<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092024000800688</article-id>
<article-id pub-id-type="doi">10.35366/120018</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia clínica del tratamiento antihipertensivo intravenoso con labetalol versus hidralazina en preeclampsia severa en la unidad de terapia intensiva obstétrica]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical efficacy of intravenous antihypertensive treatment with labetalol versus hydralazine in severe preeclampsia in obstetric intensive care unit]]></article-title>
<article-title xml:lang="pt"><![CDATA[Eficácia clínica do tratamento anti-hipertensivo intravenoso com labetalol versus hidralazina na pré-eclâmpsia grave na unidade de terapia intensiva obstétrica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortega Pérez]]></surname>
<given-names><![CDATA[Abad Quetzalcóatl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palacios Pacheco]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Téllez Becerril]]></surname>
<given-names><![CDATA[Gerardo Efraín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez Castellanos]]></surname>
<given-names><![CDATA[Priscila Magaly]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaona Valle]]></surname>
<given-names><![CDATA[Laura Soraya]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Médico «Lic. Adolfo López Mateos» Secretaría de Salud del Estado de México ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Materno Infantil del Estado de México  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>38</volume>
<numero>8</numero>
<fpage>688</fpage>
<lpage>693</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092024000800688&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092024000800688&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092024000800688&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la preeclampsia afecta entre 7-10% de los embarazos y se asocia a mayores tasas de mortalidad materna y neonatal; el tratamiento médico es el control se las cifras tensionales; el labetalol es un beta-bloqueante competitivo no selectivo y con actividad bloqueante frente a los receptores postsinápticos alfa-1 en los músculos lisos vasculares que ocasiona una vasodilatación.  Material y métodos:  ensayo clínico aleatorizado, abierto, de grupos paralelos y no doble ciego, en pacientes con preeclampsia severa.  Resultados:  se incluyeron 111 casos, 54 pacientes en el grupo de labetalol y 57 al de hidralazina. En el grupo de hidralazina hubo eventos de atonía uterina (p = 0.016) y mayor incidencia de hemorragia &gt; 500 mL (p = 0.094). Al minuto 40 entre ambos grupos se obtuvieron desenlaces similares con valores de TAS en 140 mmHg (p = 0.222), TAD de 90 mmHg (p = 0.563) y TAM de 106 mmHg (p = 0.729); hubo mayor porcentaje de neonatos con Apgar &lt; 8 al minuto en el grupo de hidralazina (p = 0.067).  Conclusiones:  el uso de labetalol en pacientes con preeclampsia severa es igual de efectivo que con hidralazina a los 40 minutos para el control hipertensivo; sin embargo, el tiempo y número de dosis fue menor en el grupo de labetalol; hubo menor hospitalización de neonatos en el grupo de labetalol.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  preeclampsia affects 7-10% of pregnancies and is associated with higher maternal and neonatal mortality rates; medical treatment is the control of blood pressure levels; labetalol is a non-selective competitive beta-blocker with blocking activity against postsynaptic alpha-1 receptors in vascular smooth muscles that causes vasodilation.  Material and methods:  randomized, open, parallel group, non-double-blind clinical trial in patients with severe preeclampsia.  Results:  111 cases were included, 54 patients in the labetalol group and 57 in the hydralazine group. In the hydralazine group there were events of uterine atony (p = 0.016) and a higher incidence of bleeding &gt; 500 mL (p = 0.094). At minute 40, similar outcomes were obtained between both groups with SBP values of 140 mmHg (p = 0.222), diastolic blood pressure (DBP) of 90 mmHg (p = 0.563) and mean arterial pressure (MAP) of 106 mmHg (p = 0.729); there was a higher percentage of neonates with Apgar &lt; 8 at one minute in the hydralazine group (p = 0.067).  Conclusions:  the use of labetalol in patients with severe preeclampsia is equally effective as hydralazine at 40 minutes for hypertensive control, however, the time and number of doses was shorter in the labetalol group; there was less hospitalization of neonates in the labetalol group.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  a pré-eclâmpsia afeta entre 7-10% das gestações e está associada a maiores taxas de mortalidade materna e neonatal; o tratamento médico consiste no controle dos níveis de pressão arterial; o labetalol é um betabloqueador competitivo não seletivo com atividade bloqueadora contra os receptores alfa-1 pós-sinápticos na musculatura lisa vascular que causa vasodilatação.  Material e métodos:  ensaio clínico randomizado, aberto, de grupos paralelos, não duplo-cego em pacientes com pré-eclâmpsia grave.  Resultados:  foram incluídos 111 casos, 54 pacientes no grupo labetalol e 57 no grupo hidralazina. No grupo hidralazina ocorreram eventos de atonia uterina (p = 0.016) e maior incidência de hemorragia &gt; 500 mL (p = 0.094). No minuto 40, resultados semelhantes foram obtidos entre os dois grupos com valores de PAS de 140 mmHg (p = 0.222), PAD de 90 mmHg (p = 0.563) e PAM de 106 mmHg (p = 0.729); Houve maior percentual de neonatos com Apgar &lt; 8 no primeiro minuto no grupo hidralazina (p = 0.067).  Conclusões:  o uso de labetalol em pacientes com pré-eclâmpsia grave é tão eficaz quanto a hidralazina aos 40 minutos para controle hipertensivo, porém o tempo e o número de doses foram menores no grupo labetalol; Houve menor internação de neonatos no grupo labetalol.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[preeclampsia]]></kwd>
<kwd lng="es"><![CDATA[labetalol]]></kwd>
<kwd lng="es"><![CDATA[hidralazina]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial y embarazo]]></kwd>
<kwd lng="en"><![CDATA[preeclampsia]]></kwd>
<kwd lng="en"><![CDATA[labetalol]]></kwd>
<kwd lng="en"><![CDATA[hydralazine]]></kwd>
<kwd lng="en"><![CDATA[arterial hypertension and pregnancy]]></kwd>
<kwd lng="pt"><![CDATA[pré-eclâmpsia]]></kwd>
<kwd lng="pt"><![CDATA[labetalol]]></kwd>
<kwd lng="pt"><![CDATA[hidralazina]]></kwd>
<kwd lng="pt"><![CDATA[hipertensão arterial e gestação]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hutcheon]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lisonkova]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Joseph]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy]]></article-title>
<source><![CDATA[Best Pract Res Clin Obstet Gynaecol]]></source>
<year>2011</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>391-403</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinkey]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Battarbee]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Bello]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Ives]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Oparil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tita]]></surname>
<given-names><![CDATA[ATN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention, diagnosis, and management of hypertensive disorders of pregnancy: a comparison of international guidelines]]></article-title>
<source><![CDATA[Curr Hypertens Rep]]></source>
<year>2020</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>66</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Magee]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Kenny]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Karumanchi]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertensive disorders of pregnancy: isshp classification, diagnosis, and management recommendations for international practice]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2018</year>
<volume>72</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-43</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimitriadis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rolnik]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada-Gutierrez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Koga]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[RPV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pre-eclampsia]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2023</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2020</year>
<volume>135</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>e237-60</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Awaludin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rahayu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Daud]]></surname>
<given-names><![CDATA[NAA]]></given-names>
</name>
<name>
<surname><![CDATA[Zakiyah]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antihypertensive medications for severe hypertension in pregnancy: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Healthcare (Basel)]]></source>
<year>2022</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>325</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Xian-Yu]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2023</year>
<volume>13</volume>
<page-range>1092501</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Finkel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rey]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Whalen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacology Lippincott's illustrated reviews]]></source>
<year>2011</year>
<edition>5th</edition>
<publisher-name><![CDATA[Lipincott, Williams &amp; Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sridharan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeira]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2018</year>
<volume>84</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1906-16</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knowles]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Mole]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2004</year>
<volume>95</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>162-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saugel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gan]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grocott]]></surname>
<given-names><![CDATA[MPW]]></given-names>
</name>
<name>
<surname><![CDATA[Myles]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Sessler]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PeriOperative Quality Initiative (POQI) international consensus statement on perioperative arterial pressure management]]></article-title>
<collab>PeriOperative Quality Initiative XI (POQI XI) Workgroup Members</collab>
<source><![CDATA[Br J Anaesth]]></source>
<year>2024</year>
<volume>133</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>264-76</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McNaughton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Joyce]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Binz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension management in emergency departments]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>2020</year>
<volume>33</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>927-34</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kulkarni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Glover]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kapil]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[SML]]></given-names>
</name>
<name>
<surname><![CDATA[Partridge]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McCormack]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hypertensive crisis: British and Irish Hypertension Society Position document]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>2023</year>
<volume>37</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>863-79</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McEvoy]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwers]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Canavan]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Ceconi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2024 ESC Guidelines for the management of elevated blood pressure and hypertension]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2024</year>
<volume>45</volume>
<numero>38</numero>
<issue>38</issue>
<page-range>3912-4018</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[S]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Novri]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Hamidy]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Savira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial]]></article-title>
<source><![CDATA[F1000Res]]></source>
<year>2023</year>
<volume>11</volume>
<page-range>1287</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mowafy]]></surname>
<given-names><![CDATA[SMS]]></given-names>
</name>
<name>
<surname><![CDATA[Medhat]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler]]></article-title>
<source><![CDATA[J Clin Monit Comput]]></source>
<year>2023</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>951-61</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bone]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Sandhu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abalos]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Khalil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prasad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2022</year>
<volume>79</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>614-28</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
